radioligand
No description yet: the sentence for this tag has not been written. 5 records carry it: 5 people.
5 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
A. Oliver Sartor Professor of Medical Oncology and Urology, Mayo Clinic · Mayo Clinic Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer. | Prostate cancer | none | prostate, trialist | ||
Jonathan R. Strosberg Section Head, Neuroendocrine Tumor Program, Moffitt Cancer Center · Moffitt Cancer Center Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours. | Neuroendocrine tumours | none | neuroendocrine, trialist | ||
Ken Herrmann Chair of Nuclear Medicine, University Hospital Essen · West German Cancer Center (WTZ), University Hospital Essen Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes. | Prostate cancer, Neuroendocrine tumours | none | nuclear-medicine, germany | ||
Louise Emmett Director of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney; Professor, UNSW · Garvan Institute of Medical Research / Kinghorn Cancer Centre Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics. | Prostate cancer | none | prostate, australia | ||
Simron Singh Medical Oncologist and Co-Director, Susan Leslie Clinic for Neuroendocrine Tumours, Sunnybrook Odette Cancer Centre · Sunnybrook Odette Cancer Centre Led NETTER-2, which moved lutetium dotatate into first-line treatment of higher-grade neuroendocrine tumours. | Neuroendocrine tumours | none | neuroendocrine, canada |